Boston, MA -- September 26, 2019 -- Today Cofactor Genomics announced that it has expanded the leadership team with the promotion of Natalie LaFranzo, PhD to Vice President of Market Development. Dr. LaFranzo’s amplified leadership role includes clinical collaboration management, corporate partnerships, and strategic marketing. Dr. LaFranzo has been with Cofactor most recently for three years, with previous roles in product management at Horizon Discovery, and marketing and communication at Red Rock Labs, after completing her PhD in Chemistry at Washington University in St. Louis.
“Natalie brings the perfect mix of analytical thinking, strategic execution, and RNA domain knowledge to her expanded role at Cofactor,” said Jarret Glasscock, CEO and founder of Cofactor Genomics. “Natalie will be taking on many new growth initiatives as we continue to scale around the high demand for our predictive immune modeling offerings.”
Cofactor also announced that it is opening a new Predictive Immune Modeling center in Kendall Square in Cambridge, Massachusetts, led by Dr. LaFranzo. The new office and facility will be the hub for the research and operations teams working with the large number of Boston-based pharma, RNA, precision medicine, and immunotherapy companies in the area.
“The Boston and Cambridge area has a deep heritage for RNA and therapeutic applications and technologies, and it’s the next logical step for scaling our business and research operations,” said LaFranzo. “Growing the Cofactor culture and increasing engagement with our partners throughout the East is an opportunity that I could not be more excited for. The community in Kendall Square, and CIC in particular, is an immersive, rich network of innovation into which Cofactor is ready to dive.”
“The field of immunotherapy is exploding with promise, and much of that growth and development is located in the Boston biotech sector. Cofactor is embedding our efforts with our partner institutions and medical centers in the area using Predictive Immune Modeling to provide the missing link between these immunotherapies and the patient populations that will respond to them,” said Glasscock.
The office will be located within the Cambridge Innovation Center (CIC) at 245 Main in Cambridge, Massachusetts. The CIC Cambridge community is home to other biotech cornerstones such as Johnson & Johnson’s JLABS with JPOD @ Boston, Boehringer Ingelheim, Affinivax, and Fujifilm Pharmaceuticals. The location will enable Cofactor to better serve its pharma partners and East Coast collaborators, and provide a hub for commercial growth.
About Cofactor Genomics
Cofactor Genomics is on a mission to enable true precision medicine through Predictive Immune Modeling. Cofactor has leveraged its experience as one of the first CAP-certified, clinical RNA sequencing laboratories to develop new methods that accurately characterize disease. Instead of searching for isolated, single-analyte biomarkers, Cofactor’s products create multidimensional biomarkers that better capture the complex immune response. Cofactor has spent years pioneering the molecular and machine learning tools to build a database of Health Expression Models, enabling advancements in Predictive Immune Modeling. Through their molecular, informatic, and database tools, Cofactor Genomics enables their partners to deliver more expedient, cost effective, and successful clinical trials. Find out more about how Cofactor Genomics is revolutionizing biomarker discovery and immuno-oncology at cofactorgenomics.com.
